What are the effects and risks of using corticosteroids in patients with dengue?

Corticosteroids Should NOT Be Used Routinely in Dengue

Corticosteroids are not recommended for dengue infection, whether in early disease or dengue shock syndrome, as they provide no mortality benefit and do not prevent progression to severe disease. The evidence consistently demonstrates lack of efficacy across multiple high-quality randomized controlled trials.

Evidence Against Corticosteroid Use

In Dengue Shock Syndrome

The strongest evidence comes from randomized controlled trials specifically examining corticosteroids in dengue shock:

• High-dose methylprednisolone (30 mg/kg) showed no mortality benefit in children with established dengue shock syndrome who failed conventional fluid resuscitation (mortality 12.5% vs 12.9% placebo, p=0.63) 1
• Hydrocortisone (50 mg/kg) demonstrated no clinical benefit in 97 patients with dengue shock - identical mortality, shock duration, and fluid requirements compared to placebo 2
• A Cochrane systematic review of 8 trials (948 participants) found no evidence of effect on death, blood transfusion needs, pulmonary hemorrhage, convulsions, or hospitalization duration in dengue shock patients 3

In Early Dengue Infection

For patients presenting early in the disease course:

• Oral prednisolone (0.5-2 mg/kg for 3 days) did not prevent shock or other complications in 225 Vietnamese patients aged 5-20 years with dengue and fever ≤72 hours 4
• The same Cochrane review found no effect on mortality, shock development, severe bleeding, thrombocytopenia, ascites, or ICU admissions when corticosteroids were given early 3
• Importantly, prednisolone failed to significantly attenuate the immune response - only 0.2% of gene transcripts were differentially expressed, with no changes in plasma cytokine levels 5

The Limited Exception: Dengue-Associated HLH

The only scenario where corticosteroids may be beneficial is in the rare complication of dengue-associated hemophagocytic lymphohistiocytosis (HLH):

• HLH occurs in approximately 12-50% of hospitalized dengue patients with cardiac involvement, though true HLH is much rarer 6
• Methylprednisolone pulse therapy has shown success in case reports of dengue-HLH 7, 8
• Look for: persistent fever despite defervescence period, progressive cytopenias, hepatosplenomegaly, hypofibrinogenemia, elevated ferritin, and hemophagocytosis on bone marrow
• This represents a distinct hyperinflammatory syndrome requiring immunomodulation, not typical dengue pathophysiology

Special Context: Septic Shock Guidelines

One guideline mentions using colloids for severe dengue shock syndrome and considering corticosteroids for refractory shock requiring escalating vasopressors 9. However, this recommendation:

• Applies to resource-limited settings where advanced critical care is unavailable
• Is intended for vasopressor-dependent shock (hydrocortisone up to 300 mg/day or prednisolone up to 75 mg/day)
• Represents general septic shock management, not dengue-specific therapy
• Contradicts the dengue-specific trial evidence showing no benefit even in established shock 2, 1

Clinical Pitfalls to Avoid

Do not use corticosteroids based on:

• Thrombocytopenia alone - this is expected in dengue and does not respond to steroids
• Plasma leakage or hemoconcentration - fluid resuscitation is the appropriate intervention
• Fear of progression to severe disease - steroids do not prevent this 3, 4
• Persistent fever - this is part of the natural disease course

The quality of evidence is low to very low 3, but consistently demonstrates lack of benefit. The trials are methodologically limited and over 20 years old for dengue shock studies, but newer trials in early disease confirm no efficacy 4.

Management Algorithm

1. Supportive care with fluid management remains the cornerstone of dengue treatment
2. Monitor for warning signs: abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, liver enlargement, rising hematocrit with falling platelets
3. Aggressive fluid resuscitation if shock develops (crystalloids or colloids in severe cases)
4. Reserve corticosteroids only for:
   • Confirmed dengue-associated HLH meeting diagnostic criteria
   • Possibly refractory vasopressor-dependent shock in resource-limited settings (though evidence is weak)

The evidence quality is insufficient to support corticosteroid use outside these narrow contexts 3.